Get the Stockscreener App
1.42
7.79%
-0.12
Pre-market:
1.48
0.06
+4.23%
Cardiff Oncology Inc stock is traded at $1.42, with a volume of 1.28M.
It is down -7.79% in the last 24 hours and down -14.97% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$1.54
Open:
$1.57
24h Volume:
1.28M
Relative Volume:
1.28
Market Cap:
$97.09M
Revenue:
$525.00K
Net Income/Loss:
$-44.76M
P/E Ratio:
-2.1347
EPS:
-0.6652
Net Cash Flow:
$-37.46M
1W Performance:
-5.33%
1M Performance:
-14.97%
6M Performance:
-41.08%
1Y Performance:
-62.73%
1-Day Range:
$1.42
$1.595
1-Week Range:
$1.42
$1.635
52-Week Range:
$1.35
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.42 | 97.09M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology (CRDF) director receives 40,565 stock options grant - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
Lucid Capital Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
CRDF Downgraded by Craig-Hallum -- Price Target Lowered to $2.00 - GuruFocus
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Update - GuruFocus
Cardiff Oncology unveils promising Phase 2 onvansertib data - TipRanks
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Cardiff Oncology Inc Call on Updated Phase 2 CRDF-004 Transcript - GuruFocus
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib By Investing.com - Investing.com Australia
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational Study - Quiver Quantitative
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The Manila Times
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades - marketscreener.com
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Sahm
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
Cardiff Oncology (CRDF) Hovering Near Support as Modest Decline ExtendsRounding Top - newsline.com
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):